SLC9A1 and breast carcinoma: Furthermore, Amiloride, an NHE1 inhibitor, demonstrated a marked antitumor activity when combined with cisplatin in 4T1 triple-negative breast tumors, whereas, when used in combination with celecoxib, it significantly reduced the incidence rates of pulmonary metastases from a primary rat mammary carcinoma [39].